Abaloparatide Pregnancy and Breastfeeding Warnings
Medically reviewed by Drugs.com. Last updated on Jan 20, 2023.
Abaloparatide is also known as: Tymlos
Abaloparatide Pregnancy Warnings
Animal reproduction studies have not been conducted. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.
This drug is not indicated for use in female patients of reproductive potential.
US FDA pregnancy category: Not assigned.
Risk Summary: No data available on use of this drug in pregnant women to inform a drug-related risk.
Abaloparatide Breastfeeding Warnings
Safety has not been established.
Comments:
-This drug is not indicated for use in female patients of reproductive potential.
-There is no information on the presence of this drug in human milk, the effects on the breastfed infant, or the effects on milk production.
Excreted into human milk: Unknown
See also
References for pregnancy information
- "Product Information. Tymlos (abaloparatide)." Radius Health (2017):
References for breastfeeding information
- "Product Information. Tymlos (abaloparatide)." Radius Health (2017):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
